 | • レポートコード：MRC9727HN7700 • 出版社/出版日：Globalinforesearch / 2026年9月 • レポート形態：英語、PDF、110ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User（1名様閲覧用） | ￥542,880 (USD3,480) | ▷ お問い合わせ |
| Multi User（10名様閲覧用） | ￥814,320 (USD5,220) | ▷ お問い合わせ |
| Corporate User（閲覧人数無制限） | ￥1,085,760 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 世界の腫瘍溶解性ウイルス療法市場規模は、2025年に3億100万米ドルと評価され、調査期間中の年平均成長率（CAGR）5.5％で推移し、2032年までに4億3600万米ドルに達すると予測されています。 腫瘍溶解性ウイルス療法は、遺伝子組み換えウイルスを用いてがん細胞を選択的に感染・破壊する生物学的治療法の一種である。ウイルスは腫瘍細胞内で増殖することで細胞溶解を誘発すると同時に、免疫系を刺激してがんに対抗させる。この技術は、ウイルスの標的化と安全性の最適化に重点を置いており、特定の腫瘍タイプに対する臨床的潜在性を提供するとともに、がん免疫療法の分野を前進させている。 レポートの範囲 本レポートは、世界の腫瘍溶解性ウイルス療法市場に関する詳細かつ包括的な分析である。定量的および定性的分析は、企業別、地域・国別、種類別、用途別に提示されています。市場は絶えず変化しているため、本レポートでは、競争状況、需給動向、および多くの市場における需要変動に寄与する主要要因について調査しています。選定された競合他社の企業概要や製品例に加え、2025年時点における主要企業の市場シェア推計値も提供されています。 主な特徴： 世界の腫瘍溶解性ウイルス療法市場の規模と予測（消費額、単位：百万ドル）、2021年～2032年 地域・国別の世界の腫瘍溶解性ウイルス療法市場の規模と予測（消費額、単位：百万ドル）、2021年～2032年 種類別および用途別の世界の腫瘍溶解性ウイルス療法市場規模および予測（消費額、百万ドル）、2021年～2032年 主要企業の世界の腫瘍溶解性ウイルス療法市場シェア（売上高、百万ドル）、2021年～2026年 本レポートの主な目的は以下の通りです： 世界および主要国における市場機会の総規模を特定すること 腫瘍溶解性ウイルス療法の成長ポテンシャルを評価すること 各製品および最終用途市場における将来の成長を予測すること 市場に影響を与える競争要因を評価すること 本レポートでは、以下のパラメータ（企業概要、売上高、粗利益率、製品ポートフォリオ、事業展開地域、および主な動向）に基づき、世界の腫瘍溶解性ウイルス療法市場における主要企業のプロファイルを紹介しています。本調査で取り上げられている主要企業には、アムジェン（AMGEN）、上海サンウェイ・バイオテック（Shanghai Sunway Biotech）、第一三共（Daiichi Sankyo）、カリディ・バイオセラピューティクス（Calidi Biotherapeutics）、レプリムーン（Replimune）、シビオノ（Sibiono）、ビンフイ・バイオファーム（Binhui Biopharm）、タスリー（Tasly）、シノファーム（Sinopharm）、バイオット（Biottt）などが含まれます。 また、本レポートでは、市場の推進要因、制約要因、機会、新製品の発売や承認に関する重要な洞察も提供しています。 腫瘍溶解性ウイルス療法市場は、タイプ別および用途別に分類されています。2021年から2032年までの期間において、各セグメントの成長状況に基づき、タイプ別および用途別の消費額について正確な算出と予測が行われています。この分析は、有望なニッチ市場をターゲットにすることで、ビジネスの拡大に役立ちます。 市場セグメンテーション タイプ別の市場セグメント 天然由来の腫瘍溶解性ウイルス療法 遺伝子組み換え腫瘍溶解性ウイルス療法 用途別の市場セグメント 固形がん 非固形がん 企業別の市場セグメント：本レポートでは以下の企業を網羅しています AMGEN Shanghai Sunway Biotech Daiichi Sankyo Calidi Biotherapeutics Replimune Sibiono Binhui Biopharm Tasly Sinopharm Biottt Sinorda 地域別の市場セグメント、地域別分析の対象 北米（米国、カナダ、メキシコ） 欧州（ドイツ、フランス、英国、ロシア、イタリア、その他の欧州諸国） アジア太平洋（中国、日本、韓国、インド、東南アジア、その他のアジア太平洋諸国） 南米（ブラジル、その他の南米諸国） 中東・アフリカ（トルコ、サウジアラビア、UAE、その他の中東・アフリカ諸国） |
The global Oncolytic Virus Therapies market size was valued at US$ 301 million in 2025 and is forecast to a readjusted size of US$ 436 million by 2032 with a CAGR of 5.5% during review period.
Oncolytic Virus Therapies are a form of biological treatment using genetically modified viruses to selectively infect and destroy cancer cells. By replicating within tumor cells, the viruses induce cell lysis while stimulating the immune system to combat cancer. The technology focuses on viral targeting and safety optimization, offering clinical potential for specific tumor types and advancing the field of cancer immunotherapy.
Report Scope
This report is a detailed and comprehensive analysis for global Oncolytic Virus Therapies market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oncolytic Virus Therapies market size and forecasts, in consumption value ($ Million), 2021-2032
Global Oncolytic Virus Therapies market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Oncolytic Virus Therapies market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Oncolytic Virus Therapies market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oncolytic Virus Therapies
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oncolytic Virus Therapies market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AMGEN, Shanghai Sunway Biotech, Daiichi Sankyo, Calidi Biotherapeutics, Replimune, Sibiono, Binhui Biopharm, Tasly, Sinopharm, Biottt, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Oncolytic Virus Therapies market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Market segment by Type
Naturally Occurring Oncolytic Virus Therapies
Genetically Modified Oncolytic Virus Therapies
Market segment by Application
Solid Tumors
Non-Solid Tumors
Market segment by players, this report covers
AMGEN
Shanghai Sunway Biotech
Daiichi Sankyo
Calidi Biotherapeutics
Replimune
Sibiono
Binhui Biopharm
Tasly
Sinopharm
Biottt
Sinorda
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Oncolytic Virus Therapies by Type
1.3.1 Overview: Global Oncolytic Virus Therapies Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Oncolytic Virus Therapies Consumption Value Market Share by Type in 2025
1.3.3 Naturally Occurring Oncolytic Virus Therapies
1.3.4 Genetically Modified Oncolytic Virus Therapies
1.4 Global Oncolytic Virus Therapies Market by Application
1.4.1 Overview: Global Oncolytic Virus Therapies Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Solid Tumors
1.4.3 Non-Solid Tumors
1.5 Global Oncolytic Virus Therapies Market Size & Forecast
1.6 Global Oncolytic Virus Therapies Market Size and Forecast by Region
1.6.1 Global Oncolytic Virus Therapies Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Oncolytic Virus Therapies Market Size by Region, (2021-2032)
1.6.3 North America Oncolytic Virus Therapies Market Size and Prospect (2021-2032)
1.6.4 Europe Oncolytic Virus Therapies Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Oncolytic Virus Therapies Market Size and Prospect (2021-2032)
1.6.6 South America Oncolytic Virus Therapies Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Oncolytic Virus Therapies Market Size and Prospect (2021-2032)
2 Company Profiles
2.1 AMGEN
2.1.1 AMGEN Details
2.1.2 AMGEN Major Business
2.1.3 AMGEN Oncolytic Virus Therapies Product and Solutions
2.1.4 AMGEN Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 AMGEN Recent Developments and Future Plans
2.2 Shanghai Sunway Biotech
2.2.1 Shanghai Sunway Biotech Details
2.2.2 Shanghai Sunway Biotech Major Business
2.2.3 Shanghai Sunway Biotech Oncolytic Virus Therapies Product and Solutions
2.2.4 Shanghai Sunway Biotech Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Shanghai Sunway Biotech Recent Developments and Future Plans
2.3 Daiichi Sankyo
2.3.1 Daiichi Sankyo Details
2.3.2 Daiichi Sankyo Major Business
2.3.3 Daiichi Sankyo Oncolytic Virus Therapies Product and Solutions
2.3.4 Daiichi Sankyo Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Daiichi Sankyo Recent Developments and Future Plans
2.4 Calidi Biotherapeutics
2.4.1 Calidi Biotherapeutics Details
2.4.2 Calidi Biotherapeutics Major Business
2.4.3 Calidi Biotherapeutics Oncolytic Virus Therapies Product and Solutions
2.4.4 Calidi Biotherapeutics Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Calidi Biotherapeutics Recent Developments and Future Plans
2.5 Replimune
2.5.1 Replimune Details
2.5.2 Replimune Major Business
2.5.3 Replimune Oncolytic Virus Therapies Product and Solutions
2.5.4 Replimune Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Replimune Recent Developments and Future Plans
2.6 Sibiono
2.6.1 Sibiono Details
2.6.2 Sibiono Major Business
2.6.3 Sibiono Oncolytic Virus Therapies Product and Solutions
2.6.4 Sibiono Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Sibiono Recent Developments and Future Plans
2.7 Binhui Biopharm
2.7.1 Binhui Biopharm Details
2.7.2 Binhui Biopharm Major Business
2.7.3 Binhui Biopharm Oncolytic Virus Therapies Product and Solutions
2.7.4 Binhui Biopharm Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Binhui Biopharm Recent Developments and Future Plans
2.8 Tasly
2.8.1 Tasly Details
2.8.2 Tasly Major Business
2.8.3 Tasly Oncolytic Virus Therapies Product and Solutions
2.8.4 Tasly Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Tasly Recent Developments and Future Plans
2.9 Sinopharm
2.9.1 Sinopharm Details
2.9.2 Sinopharm Major Business
2.9.3 Sinopharm Oncolytic Virus Therapies Product and Solutions
2.9.4 Sinopharm Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Sinopharm Recent Developments and Future Plans
2.10 Biottt
2.10.1 Biottt Details
2.10.2 Biottt Major Business
2.10.3 Biottt Oncolytic Virus Therapies Product and Solutions
2.10.4 Biottt Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Biottt Recent Developments and Future Plans
2.11 Sinorda
2.11.1 Sinorda Details
2.11.2 Sinorda Major Business
2.11.3 Sinorda Oncolytic Virus Therapies Product and Solutions
2.11.4 Sinorda Oncolytic Virus Therapies Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Sinorda Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Oncolytic Virus Therapies Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Oncolytic Virus Therapies by Company Revenue
3.2.2 Top 3 Oncolytic Virus Therapies Players Market Share in 2025
3.2.3 Top 6 Oncolytic Virus Therapies Players Market Share in 2025
3.3 Oncolytic Virus Therapies Market: Overall Company Footprint Analysis
3.3.1 Oncolytic Virus Therapies Market: Region Footprint
3.3.2 Oncolytic Virus Therapies Market: Company Product Type Footprint
3.3.3 Oncolytic Virus Therapies Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Oncolytic Virus Therapies Consumption Value and Market Share by Type (2021-2026)
4.2 Global Oncolytic Virus Therapies Market Forecast by Type (2027-2032)
5 Market Size Segment by Application
5.1 Global Oncolytic Virus Therapies Consumption Value Market Share by Application (2021-2026)
5.2 Global Oncolytic Virus Therapies Market Forecast by Application (2027-2032)
6 North America
6.1 North America Oncolytic Virus Therapies Consumption Value by Type (2021-2032)
6.2 North America Oncolytic Virus Therapies Market Size by Application (2021-2032)
6.3 North America Oncolytic Virus Therapies Market Size by Country
6.3.1 North America Oncolytic Virus Therapies Consumption Value by Country (2021-2032)
6.3.2 United States Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
6.3.3 Canada Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
6.3.4 Mexico Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
7 Europe
7.1 Europe Oncolytic Virus Therapies Consumption Value by Type (2021-2032)
7.2 Europe Oncolytic Virus Therapies Consumption Value by Application (2021-2032)
7.3 Europe Oncolytic Virus Therapies Market Size by Country
7.3.1 Europe Oncolytic Virus Therapies Consumption Value by Country (2021-2032)
7.3.2 Germany Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
7.3.3 France Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
7.3.5 Russia Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
7.3.6 Italy Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus Therapies Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Oncolytic Virus Therapies Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Oncolytic Virus Therapies Market Size by Region
8.3.1 Asia-Pacific Oncolytic Virus Therapies Consumption Value by Region (2021-2032)
8.3.2 China Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
8.3.3 Japan Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
8.3.4 South Korea Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
8.3.5 India Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
8.3.7 Australia Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
9 South America
9.1 South America Oncolytic Virus Therapies Consumption Value by Type (2021-2032)
9.2 South America Oncolytic Virus Therapies Consumption Value by Application (2021-2032)
9.3 South America Oncolytic Virus Therapies Market Size by Country
9.3.1 South America Oncolytic Virus Therapies Consumption Value by Country (2021-2032)
9.3.2 Brazil Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
9.3.3 Argentina Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus Therapies Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Oncolytic Virus Therapies Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Oncolytic Virus Therapies Market Size by Country
10.3.1 Middle East & Africa Oncolytic Virus Therapies Consumption Value by Country (2021-2032)
10.3.2 Turkey Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
10.3.4 UAE Oncolytic Virus Therapies Market Size and Forecast (2021-2032)
11 Market Dynamics
11.1 Oncolytic Virus Therapies Market Drivers
11.2 Oncolytic Virus Therapies Market Restraints
11.3 Oncolytic Virus Therapies Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Oncolytic Virus Therapies Industry Chain
12.2 Oncolytic Virus Therapies Upstream Analysis
12.3 Oncolytic Virus Therapies Midstream Analysis
12.4 Oncolytic Virus Therapies Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Oncolytic Virus Therapies Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Oncolytic Virus Therapies Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Oncolytic Virus Therapies Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Oncolytic Virus Therapies Consumption Value by Region (2027-2032) & (USD Million)
Table 5. AMGEN Company Information, Head Office, and Major Competitors
Table 6. AMGEN Major Business
Table 7. AMGEN Oncolytic Virus Therapies Product and Solutions
Table 8. AMGEN Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. AMGEN Recent Developments and Future Plans
Table 10. Shanghai Sunway Biotech Company Information, Head Office, and Major Competitors
Table 11. Shanghai Sunway Biotech Major Business
Table 12. Shanghai Sunway Biotech Oncolytic Virus Therapies Product and Solutions
Table 13. Shanghai Sunway Biotech Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Shanghai Sunway Biotech Recent Developments and Future Plans
Table 15. Daiichi Sankyo Company Information, Head Office, and Major Competitors
Table 16. Daiichi Sankyo Major Business
Table 17. Daiichi Sankyo Oncolytic Virus Therapies Product and Solutions
Table 18. Daiichi Sankyo Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Calidi Biotherapeutics Company Information, Head Office, and Major Competitors
Table 20. Calidi Biotherapeutics Major Business
Table 21. Calidi Biotherapeutics Oncolytic Virus Therapies Product and Solutions
Table 22. Calidi Biotherapeutics Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Calidi Biotherapeutics Recent Developments and Future Plans
Table 24. Replimune Company Information, Head Office, and Major Competitors
Table 25. Replimune Major Business
Table 26. Replimune Oncolytic Virus Therapies Product and Solutions
Table 27. Replimune Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. Replimune Recent Developments and Future Plans
Table 29. Sibiono Company Information, Head Office, and Major Competitors
Table 30. Sibiono Major Business
Table 31. Sibiono Oncolytic Virus Therapies Product and Solutions
Table 32. Sibiono Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Sibiono Recent Developments and Future Plans
Table 34. Binhui Biopharm Company Information, Head Office, and Major Competitors
Table 35. Binhui Biopharm Major Business
Table 36. Binhui Biopharm Oncolytic Virus Therapies Product and Solutions
Table 37. Binhui Biopharm Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. Binhui Biopharm Recent Developments and Future Plans
Table 39. Tasly Company Information, Head Office, and Major Competitors
Table 40. Tasly Major Business
Table 41. Tasly Oncolytic Virus Therapies Product and Solutions
Table 42. Tasly Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Tasly Recent Developments and Future Plans
Table 44. Sinopharm Company Information, Head Office, and Major Competitors
Table 45. Sinopharm Major Business
Table 46. Sinopharm Oncolytic Virus Therapies Product and Solutions
Table 47. Sinopharm Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Sinopharm Recent Developments and Future Plans
Table 49. Biottt Company Information, Head Office, and Major Competitors
Table 50. Biottt Major Business
Table 51. Biottt Oncolytic Virus Therapies Product and Solutions
Table 52. Biottt Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. Biottt Recent Developments and Future Plans
Table 54. Sinorda Company Information, Head Office, and Major Competitors
Table 55. Sinorda Major Business
Table 56. Sinorda Oncolytic Virus Therapies Product and Solutions
Table 57. Sinorda Oncolytic Virus Therapies Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Sinorda Recent Developments and Future Plans
Table 59. Global Oncolytic Virus Therapies Revenue (USD Million) by Players (2021-2026)
Table 60. Global Oncolytic Virus Therapies Revenue Share by Players (2021-2026)
Table 61. Breakdown of Oncolytic Virus Therapies by Company Type (Tier 1, Tier 2, and Tier 3)
Table 62. Market Position of Players in Oncolytic Virus Therapies, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 63. Head Office of Key Oncolytic Virus Therapies Players
Table 64. Oncolytic Virus Therapies Market: Company Product Type Footprint
Table 65. Oncolytic Virus Therapies Market: Company Product Application Footprint
Table 66. Oncolytic Virus Therapies New Market Entrants and Barriers to Market Entry
Table 67. Oncolytic Virus Therapies Mergers, Acquisition, Agreements, and Collaborations
Table 68. Global Oncolytic Virus Therapies Consumption Value (USD Million) by Type (2021-2026)
Table 69. Global Oncolytic Virus Therapies Consumption Value Share by Type (2021-2026)
Table 70. Global Oncolytic Virus Therapies Consumption Value Forecast by Type (2027-2032)
Table 71. Global Oncolytic Virus Therapies Consumption Value by Application (2021-2026)
Table 72. Global Oncolytic Virus Therapies Consumption Value Forecast by Application (2027-2032)
Table 73. North America Oncolytic Virus Therapies Consumption Value by Type (2021-2026) & (USD Million)
Table 74. North America Oncolytic Virus Therapies Consumption Value by Type (2027-2032) & (USD Million)
Table 75. North America Oncolytic Virus Therapies Consumption Value by Application (2021-2026) & (USD Million)
Table 76. North America Oncolytic Virus Therapies Consumption Value by Application (2027-2032) & (USD Million)
Table 77. North America Oncolytic Virus Therapies Consumption Value by Country (2021-2026) & (USD Million)
Table 78. North America Oncolytic Virus Therapies Consumption Value by Country (2027-2032) & (USD Million)
Table 79. Europe Oncolytic Virus Therapies Consumption Value by Type (2021-2026) & (USD Million)
Table 80. Europe Oncolytic Virus Therapies Consumption Value by Type (2027-2032) & (USD Million)
Table 81. Europe Oncolytic Virus Therapies Consumption Value by Application (2021-2026) & (USD Million)
Table 82. Europe Oncolytic Virus Therapies Consumption Value by Application (2027-2032) & (USD Million)
Table 83. Europe Oncolytic Virus Therapies Consumption Value by Country (2021-2026) & (USD Million)
Table 84. Europe Oncolytic Virus Therapies Consumption Value by Country (2027-2032) & (USD Million)
Table 85. Asia-Pacific Oncolytic Virus Therapies Consumption Value by Type (2021-2026) & (USD Million)
Table 86. Asia-Pacific Oncolytic Virus Therapies Consumption Value by Type (2027-2032) & (USD Million)
Table 87. Asia-Pacific Oncolytic Virus Therapies Consumption Value by Application (2021-2026) & (USD Million)
Table 88. Asia-Pacific Oncolytic Virus Therapies Consumption Value by Application (2027-2032) & (USD Million)
Table 89. Asia-Pacific Oncolytic Virus Therapies Consumption Value by Region (2021-2026) & (USD Million)
Table 90. Asia-Pacific Oncolytic Virus Therapies Consumption Value by Region (2027-2032) & (USD Million)
Table 91. South America Oncolytic Virus Therapies Consumption Value by Type (2021-2026) & (USD Million)
Table 92. South America Oncolytic Virus Therapies Consumption Value by Type (2027-2032) & (USD Million)
Table 93. South America Oncolytic Virus Therapies Consumption Value by Application (2021-2026) & (USD Million)
Table 94. South America Oncolytic Virus Therapies Consumption Value by Application (2027-2032) & (USD Million)
Table 95. South America Oncolytic Virus Therapies Consumption Value by Country (2021-2026) & (USD Million)
Table 96. South America Oncolytic Virus Therapies Consumption Value by Country (2027-2032) & (USD Million)
Table 97. Middle East & Africa Oncolytic Virus Therapies Consumption Value by Type (2021-2026) & (USD Million)
Table 98. Middle East & Africa Oncolytic Virus Therapies Consumption Value by Type (2027-2032) & (USD Million)
Table 99. Middle East & Africa Oncolytic Virus Therapies Consumption Value by Application (2021-2026) & (USD Million)
Table 100. Middle East & Africa Oncolytic Virus Therapies Consumption Value by Application (2027-2032) & (USD Million)
Table 101. Middle East & Africa Oncolytic Virus Therapies Consumption Value by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Oncolytic Virus Therapies Consumption Value by Country (2027-2032) & (USD Million)
Table 103. Global Key Players of Oncolytic Virus Therapies Upstream (Raw Materials)
Table 104. Global Oncolytic Virus Therapies Typical Customers
自律神経失調症の市場規模、疫学、治療薬販売、パイプライン、地域別展望2025-2035 The dysautonomia market reached a value of USD 2.3 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 6.2 Billion by 2035, exhibiting a growth rate (CAGR) of 9.39% during 2025-2035. The dysautonomia market has …- 世界のグリーンITサービス市場 2025年 According to our (Global Info Research) latest study, the global Green IT Services market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period. Green IT aims to minimize the negative impact of IT operations on the env…
- 耐量子暗号の世界市場2025 According to our (Global Info Research) latest study, the global Post-Quantum Cryptography market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period. This report is a detailed and comprehensive analysis for global P…
- 世界のVHH抗体医薬品市場 2025年 According to our (Global Info Research) latest study, the global VHH Antibody Drugs market size was valued at US$ xx million in 2024 and is forecast to a readjusted size of USD xx million by 2031 with a CAGR of xx% during review period. This report is a detailed and comprehensive analysis for global…
- 不妊治療の世界市場2026 According to our (Global Info Research) latest study, the global Fertility Enhancing Treatment market size was valued at US$ 6058 million in 2025 and is forecast to a readjusted size of US$ 9101 million by 2032 with a CAGR of 6.1% during review period. Infertility Drugs are drugs which enhance repro…